Fertility in male medulloblastoma survivors: closing the gaps in counseling

Leena Nahata1
Richard N Yu2
Ian P Dumont3,4
Peter E Manley3,4
Laurie E Cohen1,3,4

1Division of Endocrinology, 2Department of Urology, Department of Medicine, Boston Children’s Hospital, 3Division of Hematology/Oncology, Department of Medicine, Boston Children’s Hospital, 4Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Background: Pediatric medulloblastoma patients have high survival rates and are at risk for treatment-related sequelae, including infertility, emphasizing the need for fertility counseling. This cohort is less likely to pursue higher education, marry, and live independently, which may impact fertility counseling. Our goal was to explore fertility-related concerns in medulloblastoma survivors and counseling practices among providers.

Methods: This study was performed at the Dana-Farber/Children’s Hospital Cancer Center in Boston, Massachusetts. Surveys were administered to male pediatric medulloblastoma survivors aged 18 years and older and pediatric neuro-oncology practitioners. Medical records were reviewed to determine treatment protocols and documentation of fertility counseling. Data analysis was descriptive.

Results: Fourteen male medulloblastoma survivors and six neuro-oncology practitioners completed the study. All patients had received central nervous system irradiation and adjuvant chemotherapy with at least one alkylating agent. Five (83%) practitioners stated that they discussed fertility with all survivors at most visits. Eight (57%) medulloblastoma survivors stated that they had received fertility counseling at initial diagnosis. Six (43%) stated that fertility had been discussed since treatment had ended. The majority (>70%) of survivors reported a desire to have children and were open to learning more about their fertility status. Fertility counseling was documented in survivorship visits in only 46% of subjects.

Conclusion: Most of our subjects had no documented fertility-related discussions after completing treatment and could not recall any fertility counseling during survivorship; the majority wished to learn more about their fertility status. This suggests that the frequency with which practitioners initiate these discussions may be inadequate.

Keywords: infertility, fertility counseling, medulloblastoma, survivorship

Introduction
Central nervous system tumors are the second most common neoplasms in childhood, and 25%–30% of these tumors are medulloblastomas.1 Advances in therapeutic regimens have resulted in cure rates ranging from 60% to 85%,2,3 and significant morbidities need to be addressed in adulthood, such as sexual dysfunction and infertility.4,5 Hypogonadism resulting from oncologic treatment in these patients may be primary (due to chemotherapy) or secondary (due to radiation to the hypothalamic/pituitary axis). Primary gonadal damage is often seen in medulloblastoma patients who have received adjuvant chemotherapy.1,2,6 In a study of male brain tumor survivors, the median inhibin B level in patients who had been treated with radiation and chemotherapy was 86 pg/mL, which is indicative of impaired spermatogenesis.2

Correspondence: Leena Nahata
Division of Endocrinology, Boston Children’s Hospital, 333 Longwood Ave, Boston, MA 02115, USA
Tel +1 614 266 8856
Fax +1 617 730 0194
Email leena.nahata@childrens.harvard.edu

Clinical Oncology in Adolescents and Young Adults 2013:3 89–94
Dovepress

http://dx.doi.org/10.2147/COAYA.S53817

Clinical Oncology in Adolescents and Young Adults downloaded from https://www.dovepress.com/ by 54.70.40.11 on 14-Jan-2019 For personal use only.
Materials and methods

This was a cross-sectional study at a single institution, consisting of surveys administered to male pediatric medulloblastoma survivors and pediatric neuro-oncology practitioners.

Patient survey methods

Institutional review board approval was obtained to conduct a telephone survey of all male medulloblastoma survivors aged 18 years and older seen in the past 20 years at the Stop and Shop Family Pediatric Brain Tumor long-term follow-up clinic at Dana-Farber/Children’s Hospital Cancer Center (DF/CHCC) in Boston, Massachusetts.

Inclusion criteria were as follows: male gender, history of medulloblastoma, and current age ≥ 18 years. Subjects were excluded if they had a documented history of intellectual disability or pervasive developmental disorder, or if prior neurologic testing had shown a reading level below 8th grade ability. Subjects were sent a letter describing the study with an opt-out card. A single study team member then contacted the subjects via telephone to complete the surveys.

Practitioner survey methods

All of the pediatric neuro-oncology medical and pediatric nurse practitioners at DF/CHCC were asked to complete a survey about their fertility counseling practices in males with medulloblastoma.

Additional data collection and analysis

Retrospective chart review was completed to determine treatment protocols and whether fertility counseling had been documented before and after treatment. Data analysis was descriptive.

Results

Patient survey data

Twenty-one male medulloblastoma survivors met the inclusion criteria. None were eliminated based on the exclusion criteria. Three subjects returned the opt-out cards, and four were unable to be contacted using the phone numbers in their medical records. All of the remaining subjects (n=14) who were contacted agreed to participate; survey results are presented in Table 1. The current age of this sample was 18–32 (median 24) years. Age at medulloblastoma diagnosis was 3–19 (median 13.5) years.
Practitioner survey data
All six practitioners (two nurse practitioners and four attending physicians) from the Pediatric Neuro-Oncology program at DF/CHCC completed surveys about their fertility counseling practices at time of medulloblastoma diagnosis and during survivorship (Table 2), and about barriers to fertility counseling (Tables 3 and 4).

Electronic medical record data
Treatment regimens were reviewed for this cohort as a whole. All patients had been treated with 23.4–36 Gy whole brain and spine radiation with a boost to the posterior fossa to 50.4–54 Gy. They had received adjuvant chemotherapy with cisplatin, vincristine, and lomustine (450–600 mg/m²) and/or cyclophosphamide (4.5–24 g/m²). Based on these treatments, all patients contacted were felt to be at risk for infertility.1,7

Medical records from the initial oncologic consultation were found for 12 of 14 patients. In six of the 12 evaluable cases (50%), infertility was mentioned as a potential side effect of oncologic treatment. In five of the other six cases where infertility was not discussed, the patients were prepubertal at the time of diagnosis.

Documentation from survivorship visits was found in 13 of 14 patients. In six of 13 subjects (46%), discussions with the survivors about fertility issues were documented. In five patients’ records (38%), there was no mention of fertility. In two cases (15%), the possibility of infertility was mentioned in the notes but it was unclear whether this had been discussed with the patient.

**Discussion**
Preservation of reproductive capacity is recognized as an important component of a cancer survivor’s quality of life. The majority of patients in our study had been treated with central nervous system radiation and alkylating agents (at doses that have been reported to cause gonadal dysfunction), putting them at risk for primary and secondary hypogonadism.23,24 Fortunately, most adolescent patients in our study had received pretreatment fertility counseling, and the majority of those boys did attempt to bank sperm.

Fertility also needs to be readdressed after treatment is complete, as many pediatric cancer survivors may not recall the potential side effects of their oncologic treatment once they reach adulthood and consider having children.20,25 Additionally, some patients may have transient suppression of spermatogenesis after treatment with gradual recovery over time, highlighting the importance of routine surveillance.

**Table 1 Fertility concerns among medulloblastoma survivors (n=14)**

<table>
<thead>
<tr>
<th>Question</th>
<th>Response, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Was infertility discussed at initial diagnosis?</td>
<td>8 (57)</td>
</tr>
<tr>
<td>2 Was sperm banking discussed at initial diagnosis?</td>
<td>6 (43)</td>
</tr>
<tr>
<td>If sperm banking was discussed, was an attempt to sperm bank made?</td>
<td>4 (67)*</td>
</tr>
<tr>
<td>If an attempt was made, was an adequate sample produced?</td>
<td>3 (75)*</td>
</tr>
<tr>
<td>3 Has fertility been discussed since treatment ended?</td>
<td>6 (43)</td>
</tr>
<tr>
<td>4 Have you been in a serious romantic relationship after treatment?</td>
<td>6 (43)</td>
</tr>
<tr>
<td>5 Are you concerned about fertility?</td>
<td>1 (7)</td>
</tr>
<tr>
<td>6 Do you want to have children?</td>
<td>10 (71)</td>
</tr>
<tr>
<td>7 Have you ever tried to have a biological child?</td>
<td>0 (0)</td>
</tr>
<tr>
<td>8 Are you interested in learning more about your fertility status?</td>
<td>11 (79)</td>
</tr>
</tbody>
</table>

Note: *The percentages are based on the total number in question 2.

**Table 2 Frequency of fertility counseling (n=6)**

<table>
<thead>
<tr>
<th>Question</th>
<th>Always</th>
<th>Most of the time</th>
<th>Sometimes</th>
<th>Rarely</th>
<th>Never</th>
</tr>
</thead>
<tbody>
<tr>
<td>In male patients with medulloblastoma, infertility is a side effect that is seen</td>
<td>0 (0)</td>
<td>1 (17)</td>
<td>5 (83)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>I discuss fertility preservation with families of male medulloblastoma patients ≥13 years</td>
<td>0 (0)</td>
<td>2 (33)</td>
<td>2 (33)</td>
<td>2 (33)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>With all survivors, routinely, at all visits</th>
<th>With all survivors, at some visits</th>
<th>Only in survivors who raise a concern about their fertility</th>
</tr>
</thead>
<tbody>
<tr>
<td>In male patients 18 years and older who have completed treatment for medulloblastoma, I initiate discussions about fertility</td>
<td>1 (17)</td>
<td>4 (67)</td>
</tr>
</tbody>
</table>
of the hypothalamic-pituitary-gonadal axis. Childhood cancer survivors are known to have anxiety about interpersonal relationships, sexual function, and fatherhood. Misconceptions about their fertility status may lead to unnecessary anxiety, or in other cases, may result in unintentional pregnancies. Further, moderate to severe oligospermia has been shown to progress to azoospermia over time. Therefore, patients with persistent moderate to severe oligospermia after treatment should consider banking their sperm if this was not completed prior to therapy.

Medulloblastoma survivors who have received craniospinal irradiation and gonadotoxic chemotherapeutic agents, such as the subjects in our study, may have primary gonadal damage that is underdiagnosed due to follicle-stimulating hormone levels that appear to be “normal” or even low due to superimposed secondary hypogonadism. Inhibit B levels may help in assessing gonadal function, but have been shown in some studies to have low specificity and positive predictive value for azoospermia, and thus should be interpreted in conjunction with careful physical examination and semen analysis. Relying on biochemical testing alone to counsel these patients about their fertility status can provide inadequate or even inaccurate information; these survivors should thus be referred to fertility specialists for a more detailed evaluation. Given that the majority of our practitioners felt that they had inadequate information to counsel patients about fertility preservation, routinely involving a fertility specialist should be considered, as suggested by the American Academy of Pediatrics.

Consistent with studies in other pediatric cancer patients, there was significant variation between our providers in their reported frequency of fertility counseling. In survivorship, most practitioners stated that they discuss fertility with all survivors at some visits. However, our chart review demonstrated that a significant number of subjects had no documented discussions about their fertility status with their providers since treatment had ended, and in the transition to adulthood. This discrepancy suggests that the frequency with which practitioners initiate these discussions may be inadequate, or that miscommunication exists between practitioners and survivors surrounding these topics. Perhaps because medulloblastoma survivors are less likely to complete education, have careers, live independently, and marry, their health care providers may actually initiate discussions about fertility less often than they realize.

Although the majority of medulloblastoma survivors in our study stated that they were not concerned about fertility, most of them expressed a desire to have children and were open to learning more about their fertility status. This was true even in survivors who had not recently been in a serious romantic relationship, and in those who had never lived independently. Of note, some of these factors were identified by practitioners as influencing whether they would initiate a discussion about fertility. This discrepancy is similar to findings in previous studies of other cancer survivors, where many survivors stated that they were “uncertain” about their

Table 3 Barriers to fertility counseling at time of diagnosis (n=6)

<table>
<thead>
<tr>
<th>Question</th>
<th>Agree strongly</th>
<th>Agree somewhat</th>
<th>Disagree somewhat</th>
<th>Disagree strongly</th>
</tr>
</thead>
<tbody>
<tr>
<td>All male patients undergoing cancer treatment with infertility as a potential side effect should be offered sperm banking</td>
<td>3 (50)</td>
<td>3 (50)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>My patients are typically too ill to attempt sperm banking</td>
<td>0 (0)</td>
<td>2 (33)</td>
<td>2 (33)</td>
<td>2 (33)</td>
</tr>
<tr>
<td>The urgency to start treatment makes it difficult to discuss and complete sperm banking adequately</td>
<td>0 (0)</td>
<td>3 (50)</td>
<td>2 (33)</td>
<td>1 (17)</td>
</tr>
<tr>
<td>I do not have time in a busy clinic to discuss sperm banking adequately</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>5 (83)</td>
<td>1 (17)</td>
</tr>
<tr>
<td>I do not have knowledge/information to counsel patients adequately about sperm banking</td>
<td>0 (0)</td>
<td>4 (66)</td>
<td>2 (33)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>It is uncomfortable to discuss sperm banking with patients because it is such an emotional and intimate topic</td>
<td>0 (0)</td>
<td>1 (17)</td>
<td>2 (33)</td>
<td>3 (50)</td>
</tr>
<tr>
<td>Sperm banking is the only option I can offer to my patients for fertility preservation</td>
<td>0 (0)</td>
<td>2 (33)</td>
<td>3 (50)</td>
<td>1 (17)</td>
</tr>
<tr>
<td>The success rates of infertility treatments making use of frozen sperm are too young to justify banking sperm</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>2 (33)</td>
<td>4 (66)</td>
</tr>
<tr>
<td>I am less likely to discuss fertility preservation with patients whose overall prognosis is poor</td>
<td>1 (17)</td>
<td>2 (33)</td>
<td>3 (50)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

Table 4 Barriers to fertility counseling in survivorship (n=6)

<table>
<thead>
<tr>
<th>Prompt</th>
<th>Response, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I am less likely to initiate a discussion about fertility in survivors who:</td>
<td>True False</td>
</tr>
<tr>
<td>Have never had a serious romantic relationship</td>
<td>0 (0) 6 (100)</td>
</tr>
<tr>
<td>Have never expressed a desired to have children</td>
<td>1 (17) 5 (83)</td>
</tr>
<tr>
<td>Have never lived independently</td>
<td>2 (33) 4 (67)</td>
</tr>
<tr>
<td>Have banked sperm in the past</td>
<td>0 (0) 6 (100)</td>
</tr>
<tr>
<td>Have not banked sperm in the past</td>
<td>0 (0) 6 (100)</td>
</tr>
</tbody>
</table>
Fertility counseling in male medulloblastoma survivors

Livestrong Foundation (agencies such as Fertile Hope (www.fertilehope.org) and the Livestrong Foundation (www.livestrong.org) for additional information and psychosocial support. Larger studies of pediatric brain tumor survivors may help optimize fertility counseling in this unique population. Standardized fertility counseling guidelines should be implemented to ensure best clinical practice.

Disclosure

The authors report no conflicts of interest in this work.

References